GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Revenue

Valneva SE (Valneva SE) Revenue : $165.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Revenue?

Valneva SE's revenue for the three months ended in Dec. 2023 was $45.7 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $165.8 Mil. Valneva SE's Revenue per Share for the three months ended in Dec. 2023 was $0.33. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.20.

Warning Sign:

Valneva SE revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Valneva SE was -64.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Valneva SE's highest 3-Year average Revenue per Share Growth Rate was 88.40% per year. The lowest was -29.20% per year. And the median was 21.70% per year.


Valneva SE Revenue Historical Data

The historical data trend for Valneva SE's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Revenue Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 140.22 134.21 393.32 382.74 167.63

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.01 35.88 43.59 40.63 45.69

Competitive Comparison of Valneva SE's Revenue

For the Biotechnology subindustry, Valneva SE's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Revenue distribution charts can be found below:

* The bar in red indicates where Valneva SE's Revenue falls into.



Valneva SE Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $165.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (OTCPK:INRLF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Valneva SE Revenue Related Terms

Thank you for viewing the detailed overview of Valneva SE's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (Valneva SE) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.